Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A CRL citing manufacturing, not efficacy raised whether to drop a secondary endpoint that will dominate the AdCom for RWE evidence-strategy director at a 505(b)(2) program relying on literature plus a bridging study. Scientific-advice briefing book is incomplete relative to that question, so Hold remains live until the file is complete.

DECISION RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. Scientific-advice briefing book reads as Proceed under protocol once a CRL citing manufacturing, not efficacy is lined up to the same Pharma & Life Sciences population. 2. Scientific-advice briefing book is closer to Pause the pathway after a CRL citing manufacturing, not efficacy; Proceed under protocol would over-claim this FDA Response and Labeling extract. 3. Escalate safety review is still live in scientific-advice briefing book for RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study. 4. Scientific-advice briefing book is missing the fact RWE evidence-strategy director needs after a CRL citing manufacturing, not efficacy; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 3. Check whether scientific-advice briefing book supports the labeled claim RWE evidence-strategy director would keep. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read scientific-advice briefing book against a CRL citing manufacturing, not efficacy and write the one fact that would move to drop a secondary for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (scientific-advice briefing book after a CRL citing manufacturing, not efficacy). The follow-on FDA Response and Labeling action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in scientific-advice briefing book, then the action for RWE evidence-strategy director - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Missing page in scientific-advice briefing book after a CRL citing manufacturing, not efficacy, if any - Regulatory or exam hook FDA Response and Labeling would cite